EMA Recommends Extension of Indications for Dostarlimab By Ogkologos - January 23, 2025 679 0 Facebook Twitter Google+ Pinterest WhatsApp Change concerns the first-line treatment of patients with endometrial cancer Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR How to Talk About Advanced Cancer Care Planning: An Expert Discussion November 20, 2023 FDA Approves Cemiplimab-rwlc in Combination with Platinum-Based Chemotherapy for Advanced NSCLC November 25, 2022 Adding Atezolizumab to Cabozantinib Fails to Improve Clinical Outcomes and Increases... June 13, 2023 New breast and lung cancer treatments approved in Scotland January 19, 2022 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Atezolizumab FDA Approves Nivolumab in Combination with Chemotherapy for Metastatic Gastric Cancer... Moxetumomab Approved by FDA for Hairy Cell Leukemia Penn State Researchers Working on Amazon Alexa Skill for Metastatic Breast...
